硝酸钾在射血分数保留的心力衰竭中的随机临床试验
这项多中心随机双盲交叉试验纳入84例有症状且左室充盈压升高的HFpEF患者,比较硝酸钾与氯化钾各6周对运动耐量的影响。硝酸钾虽显著升高血清一氧化氮代谢物,但未改善峰值摄氧量、总做功、血管舒张储备或生活质量。
核心结论
- 在HFpEF患者中,慢性硝酸钾给药未改善有氧能力、总做功或生活质量。
研究设计与样本
- 多中心随机双盲交叉试验,2016年10月至2022年7月在宾夕法尼亚大学、费城退伍军人医疗中心和西北大学开展,纳入84例有症状(NYHA II/III级)且有左室充盈压升高客观证据的HFpEF患者。
主要发现
- 峰值摄氧量硝酸钾组10.23(SD, 0.43)mL/min/kg vs 氯化钾组10.17(SD, 0.43)mL/min/kg,P = .73。
- 运动总做功硝酸钾组25.9(SD, 3.65)千焦 vs 氯化钾组23.63(SD, 3.63)千焦,P = .29。
- 硝酸钾未改善运动系统性血管舒张储备或堪萨斯城心肌病问卷评估的生活质量,但耐受性良好。
临床怎么用
- 对于HFpEF患者,慢性无机硝酸盐补充不应作为改善运动耐量或生活质量的常规策略。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nitric oxide deficiency may contribute to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). Prior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorganic nitrate administration. OBJECTIVE: To assess the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with HFpEF. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized double-blinded crossover trial was conducted at the University of Pennsylvania, the Philadelphia Veterans Affairs Medical Center, and Northwestern University between October 2016 and July 2022. Participants included patients with symptomatic (New York Heart Association class II/III) HFpEF who had objective signs of elevated left ventricular filling pressures. Image quantification, physiological data modeling and biochemical measurements, unblinding, and statistical analyses were completed in 2024. INTERVENTION: Potassium nitrate (KNO3) (6 mmol 3 times daily) vs equimolar doses of potassium chloride (KCl) for 6 weeks, each with a 1-week washout in between. MAIN OUTCOMES AND MEASURES: The coprimary end points included peak oxygen uptake and total work performed during a maximal effort incremental cardiopulmonary exercise test. Secondary end points included the exercise systemic vasodilatory reserve (ie, reduction in systemic vascular resistance with exercise) and quality of life assessed using the Kansas City Cardiomyopathy Questionnaire. RESULTS: Eighty-four participants were enrolled. Median age was 68 years and 58 participants were women (69.0%). Most participants had NYHA class II disease (69%) with a mean 6-minute walk distance of 335.5 (SD, 97.3) m. Seventy-seven participants received the KNO3 intervention and 74 received the KCl intervention. KNO3 increased trough levels of serum nitric oxide metabolites after 6 weeks (KNO3, 418.4 [SD, 26.9] uM vs KCl, 40.1 [SD, 28.3] uM; P < .001). KNO3 did not improve peak oxygen uptake (KNO3, 10.23 [SD, 0.43] mL/min/kg vs KCl, 10.17 [SD, 0.43] mL/min/kg; P = .73) or total work performed (KNO3, 25.9 [SD, 3.65] kilojoules vs KCl, 23.63 [SD, 3.63] kilojoules; P = .29). KNO3 nitrate did not improve the vasodilatory reserve or quality of life, though it was well-tolerated. CONCLUSIONS AND RELEVANCE: In this study, potassium nitrate did not improve aerobic capacity, total work, or quality of life in participants with HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02840799.
引用
- Zamani, Shah, Cohen, et al. Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 39693096. doi:10.1001/jamacardio.2024.4417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。